B
Regeneron Pharmaceuticals, Inc.
REGN
$890.68
-$15.86-1.75%
B
Buy
10/16/2023Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 10/16/2023 due to a major increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 10/16/2023 due to a major increase in the total return index and volatility index.
B
Buy
8/4/2023Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 8/4/2023 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $7.17 to $8.5, and EBIT increased 1.37% from $1B to $1.02B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 8/4/2023 due to a noticeable increase in the growth index, volatility index and valuation index. Earnings per share increased from $7.17 to $8.5, and EBIT increased 1.37% from $1B to $1.02B.
C
Hold
8/2/2023Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 8/2/2023 due to a decline in the efficiency index, volatility index and total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 8/2/2023 due to a decline in the efficiency index, volatility index and total return index.
B
Buy
7/18/2023Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 7/18/2023 due to an increase in the volatility index and valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 7/18/2023 due to an increase in the volatility index and valuation index.
C
Hold
7/3/2023Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 7/3/2023 due to a substantial decline in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 7/3/2023 due to a substantial decline in the total return index and volatility index.
B
Buy
5/5/2023Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 5/5/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 31.68% from $1.2B to $817.8M, earnings per share declined from $10.4926 to $7.17, and operating cash flow declined 20.48% from $1.72B to $1.37B.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 5/5/2023 due to a noticeable decline in the growth index, efficiency index and valuation index. Net income declined 31.68% from $1.2B to $817.8M, earnings per share declined from $10.4926 to $7.17, and operating cash flow declined 20.48% from $1.72B to $1.37B.
B
Buy
3/30/2023Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/30/2023 due to an increase in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/30/2023 due to an increase in the total return index.
B
Buy
3/8/2023Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 3/8/2023 due to a noticeable decline in the total return index, growth index and valuation index. Earnings per share declined from $11.66 to $10.4926, and EBIT declined 3.83% from $1.22B to $1.18B.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 3/8/2023 due to a noticeable decline in the total return index, growth index and valuation index. Earnings per share declined from $11.66 to $10.4926, and EBIT declined 3.83% from $1.22B to $1.18B.
B
Buy
10/21/2022Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 10/21/2022 due to a noticeable increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 10/21/2022 due to a noticeable increase in the total return index and volatility index.
B
Buy
7/1/2022Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 7/1/2022 due to a large decline in the total return index and growth index. Earnings per share declined from $19.6909 to $8.61, EBIT declined 51.26% from $2.64B to $1.29B, and total revenue declined 40.12% from $4.95B to $2.97B.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 7/1/2022 due to a large decline in the total return index and growth index. Earnings per share declined from $19.6909 to $8.61, EBIT declined 51.26% from $2.64B to $1.29B, and total revenue declined 40.12% from $4.95B to $2.97B.
B
Buy
3/15/2022Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/15/2022 due to a noticeable increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/15/2022 due to a noticeable increase in the total return index and volatility index.
B
Buy
2/25/2022Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 2/25/2022 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 3.03 to 2.98.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 2/25/2022 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 3.03 to 2.98.
B
Buy
2/7/2022Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 2/7/2022 due to a major increase in the total return index, growth index and valuation index. Operating cash flow increased 444.69% from $626.7M to $3.41B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 2/7/2022 due to a major increase in the total return index, growth index and valuation index. Operating cash flow increased 444.69% from $626.7M to $3.41B.
B
Buy
11/3/2021Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 11/3/2021 due to an increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 11/3/2021 due to an increase in the total return index and volatility index.
C
Hold
10/8/2021Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/8/2021 due to a decline in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/8/2021 due to a decline in the total return index.
B
Buy
9/17/2021Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 9/17/2021 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 2.39 to 2.92, and debt to equity declined from 0.23 to 0.18.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 9/17/2021 due to an increase in the total return index, valuation index and solvency index. The quick ratio increased from 2.39 to 2.92, and debt to equity declined from 0.23 to 0.18.
C
Hold
6/1/2021Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 6/1/2021 due to an increase in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 6/1/2021 due to an increase in the total return index.
C
Hold
5/17/2021Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 5/17/2021 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 45.69% from $1.23B to $668.5M, and earnings per share declined from $10.2411 to $10.09.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 5/17/2021 due to a decline in the growth index, total return index and volatility index. Operating cash flow declined 45.69% from $1.23B to $668.5M, and earnings per share declined from $10.2411 to $10.09.
C
Hold
10/15/2020Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/15/2020 due to a decline in the total return index and valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/15/2020 due to a decline in the total return index and valuation index.
B
Buy
9/30/2020Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 9/30/2020 due to an increase in the total return index and valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 9/30/2020 due to an increase in the total return index and valuation index.
C
Hold
9/15/2020Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 9/15/2020 due to a large decline in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 9/15/2020 due to a large decline in the total return index.
B
Buy
8/25/2020Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 8/25/2020 due to a decline in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 8/25/2020 due to a decline in the total return index.
B
Buy
8/6/2020Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from C+ on 8/6/2020 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from $5.43 to $7.61, operating cash flow increased 35.16% from $698M to $943.4M, and total revenue increased 6.77% from $1.83B to $1.95B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from C+ on 8/6/2020 due to a substantial increase in the growth index, total return index and volatility index. Earnings per share increased from $5.43 to $7.61, operating cash flow increased 35.16% from $698M to $943.4M, and total revenue increased 6.77% from $1.83B to $1.95B.
C
Hold
5/6/2020Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 5/6/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Net income declined 21.14% from $792M to $624.6M, total revenue declined 15.73% from $2.17B to $1.83B, and operating cash flow declined 11.35% from $787.4M to $698M.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 5/6/2020 due to a noticeable decline in the growth index, solvency index and efficiency index. Net income declined 21.14% from $792M to $624.6M, total revenue declined 15.73% from $2.17B to $1.83B, and operating cash flow declined 11.35% from $787.4M to $698M.
B
Buy
5/5/2020Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 5/5/2020 due to a substantial increase in the total return index, efficiency index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 5/5/2020 due to a substantial increase in the total return index, efficiency index and volatility index.
C
Hold
3/16/2020Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 3/16/2020 due to a noticeable increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 3/16/2020 due to a noticeable increase in the total return index and volatility index.
C
Hold
12/3/2019Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C from C- on 12/3/2019 due to an increase in the growth index, volatility index and efficiency index. Earnings per share increased from $1.68 to $5.86, net income increased 246.76% from $193.1M to $669.6M, and operating cash flow increased 195.96% from $188.3M to $557.3M.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C from C- on 12/3/2019 due to an increase in the growth index, volatility index and efficiency index. Earnings per share increased from $1.68 to $5.86, net income increased 246.76% from $193.1M to $669.6M, and operating cash flow increased 195.96% from $188.3M to $557.3M.
C
Hold
7/9/2019Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C- from C on 7/9/2019 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $7.1447 to $3.99, EBIT declined 33.15% from $718.06M to $480M, and total revenue declined 11.2% from $1.93B to $1.71B.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C- from C on 7/9/2019 due to a noticeable decline in the growth index, total return index and volatility index. Earnings per share declined from $7.1447 to $3.99, EBIT declined 33.15% from $718.06M to $480M, and total revenue declined 11.2% from $1.93B to $1.71B.
C
Hold
4/18/2019Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from B- on 4/18/2019 due to a decline in the volatility index and total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from B- on 4/18/2019 due to a decline in the volatility index and total return index.
B
Buy
4/12/2019Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 4/12/2019 due to an increase in the total return index, volatility index and valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 4/12/2019 due to an increase in the total return index, volatility index and valuation index.
C
Hold
3/4/2019Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 3/4/2019 due to a large increase in the total return index, valuation index and growth index. Operating cash flow increased 60.9% from $452.96M to $728.83M, earnings per share increased from $5.17 to $7.1447, and total revenue increased 15.89% from $1.66B to $1.93B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 3/4/2019 due to a large increase in the total return index, valuation index and growth index. Operating cash flow increased 60.9% from $452.96M to $728.83M, earnings per share increased from $5.17 to $7.1447, and total revenue increased 15.89% from $1.66B to $1.93B.
C
Hold
8/21/2018Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C from C- on 8/21/2018 due to an increase in the volatility index, total return index and growth index. Earnings per share increased from $4.16 to $4.82, EBIT increased 9.69% from $567.23M to $622.19M, and total revenue increased 6.39% from $1.51B to $1.61B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C from C- on 8/21/2018 due to an increase in the volatility index, total return index and growth index. Earnings per share increased from $4.16 to $4.82, EBIT increased 9.69% from $567.23M to $622.19M, and total revenue increased 6.39% from $1.51B to $1.61B.
C
Hold
6/13/2018Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C- from D+ on 6/13/2018 due to an increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C- from D+ on 6/13/2018 due to an increase in the total return index and volatility index.
D
Sell
5/10/2018Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to D+ from C- on 5/10/2018 due to a decline in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to D+ from C- on 5/10/2018 due to a decline in the total return index and volatility index.
C
Hold
2/14/2018Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C- from C on 2/14/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Net income declined 55.32% from $388.32M to $173.52M.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C- from C on 2/14/2018 due to a noticeable decline in the total return index, volatility index and efficiency index. Net income declined 55.32% from $388.32M to $173.52M.
C
Hold
11/30/2017Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 11/30/2017 due to a noticeable decline in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 11/30/2017 due to a noticeable decline in the total return index and volatility index.
C
Hold
10/13/2017Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/13/2017 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 108.59% from $355.9M to -$30.57M.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/13/2017 due to a large decline in the growth index, total return index and volatility index. Operating cash flow declined 108.59% from $355.9M to -$30.57M.
B
Buy
7/18/2017Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 7/18/2017 due to a major increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 7/18/2017 due to a major increase in the total return index and volatility index.
C
Hold
5/15/2017Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 5/15/2017 due to an increase in the volatility index, efficiency index and valuation index. Total capital increased 13.1% from $4.93B to $5.57B.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 5/15/2017 due to an increase in the volatility index, efficiency index and valuation index. Total capital increased 13.1% from $4.93B to $5.57B.
C
Hold
12/20/2016Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 12/20/2016 due to a decline in the total return index and efficiency index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 12/20/2016 due to a decline in the total return index and efficiency index.
C
Hold
8/23/2016Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 8/23/2016 due to an increase in the valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 8/23/2016 due to an increase in the valuation index.
C
Hold
8/8/2016Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 8/8/2016 due to a decline in the valuation index, total return index and efficiency index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 8/8/2016 due to a decline in the valuation index, total return index and efficiency index.
C
Hold
7/11/2016Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 7/11/2016 due to an increase in the volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 7/11/2016 due to an increase in the volatility index.
C
Hold
6/24/2016Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 6/24/2016 due to a decline in the volatility index, total return index and efficiency index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 6/24/2016 due to a decline in the volatility index, total return index and efficiency index.
C
Hold
6/8/2016Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 6/8/2016 due to a major increase in the growth index, valuation index and efficiency index. EBIT increased 42.51% from $231.08M to $329.31M, total revenue increased 9.36% from $1.1B to $1.2B, and earnings per share increased from $1.34 to $1.4514.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 6/8/2016 due to a major increase in the growth index, valuation index and efficiency index. EBIT increased 42.51% from $231.08M to $329.31M, total revenue increased 9.36% from $1.1B to $1.2B, and earnings per share increased from $1.34 to $1.4514.
C
Hold
3/11/2016Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C from C+ on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
C
Hold
2/12/2016Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 2/12/2016 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 68.44% from $892.85M to $281.82M, EBIT declined 41.11% from $392.42M to $231.08M, and earnings per share declined from $1.8159 to $1.34.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 2/12/2016 due to a significant decline in the growth index, total return index and volatility index. Operating cash flow declined 68.44% from $892.85M to $281.82M, EBIT declined 41.11% from $392.42M to $231.08M, and earnings per share declined from $1.8159 to $1.34.
B
Buy
11/12/2015Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 11/12/2015 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 3.32 to 3.18.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 11/12/2015 due to a noticeable decline in the total return index and solvency index. The quick ratio declined from 3.32 to 3.18.
B
Buy
11/2/2015Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 11/2/2015 due to an increase in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 11/2/2015 due to an increase in the total return index.
B
Buy
9/3/2015Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 9/3/2015 due to a noticeable decline in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 9/3/2015 due to a noticeable decline in the total return index.
B
Buy
8/6/2015Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 8/6/2015 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from $0.66 to $1.69, EBIT increased 21.62% from $283.55M to $344.86M, and total revenue increased 14.83% from $869.61M to $998.62M.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 8/6/2015 due to a large increase in the growth index, total return index and valuation index. Earnings per share increased from $0.66 to $1.69, EBIT increased 21.62% from $283.55M to $344.86M, and total revenue increased 14.83% from $869.61M to $998.62M.
B
Buy
5/8/2015Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 5/8/2015 due to a large decline in the growth index, efficiency index and volatility index. Operating cash flow declined 144.13% from $198.28M to -$87.5M, earnings per share declined from $0.9668 to $0.66, and net income declined 31% from $110.18M to $76.02M.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to B- from B on 5/8/2015 due to a large decline in the growth index, efficiency index and volatility index. Operating cash flow declined 144.13% from $198.28M to -$87.5M, earnings per share declined from $0.9668 to $0.66, and net income declined 31% from $110.18M to $76.02M.
B
Buy
3/16/2015Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/16/2015 due to an increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B from B- on 3/16/2015 due to an increase in the total return index and volatility index.
B
Buy
2/13/2015Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 2/13/2015 due to a substantial increase in the growth index, efficiency index and volatility index. Net income increased 38.2% from $79.72M to $110.18M, earnings per share increased from $0.7028 to $0.9668, and EBIT increased 35.38% from $182.72M to $247.37M.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 2/13/2015 due to a substantial increase in the growth index, efficiency index and volatility index. Net income increased 38.2% from $79.72M to $110.18M, earnings per share increased from $0.7028 to $0.9668, and EBIT increased 35.38% from $182.72M to $247.37M.
C
Hold
10/16/2014Downgrade
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/16/2014 due to a decline in the total return index.
Regeneron Pharmaceuticals, Inc. (REGN) was downgraded to C+ from B- on 10/16/2014 due to a decline in the total return index.
B
Buy
10/1/2014Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 10/1/2014 due to a significant increase in the total return index and volatility index.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to B- from C+ on 10/1/2014 due to a significant increase in the total return index and volatility index.
C
Hold
8/7/2014Upgraded
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 8/7/2014 due to a significant increase in the growth index, efficiency index and solvency index. Operating cash flow increased 512.38% from $53.53M to $327.79M, net income increased 41.7% from $65.44M to $92.74M, and earnings per share increased from $0.58 to $0.82.
Regeneron Pharmaceuticals, Inc. (REGN) was upgraded to C+ from C on 8/7/2014 due to a significant increase in the growth index, efficiency index and solvency index. Operating cash flow increased 512.38% from $53.53M to $327.79M, net income increased 41.7% from $65.44M to $92.74M, and earnings per share increased from $0.58 to $0.82.
NASDAQ
04/25/2024 4:00PM Eastern
Quotes delayed
